IL MAKIAGE Acquires Leading Israeli Computer Vision Startup Voyage81
IL MAKIAGE, the fastest growing beauty company in the U.S., today announces the acquisition of Voyage81, a deep-tech AI-based computational imaging startup. IL MAKIAGE’s acquisition of Voyage81 will enable the company to use Voyage81’s patented hyperspectral imaging systems to further enhance the company’s machine learning capabilities and aligns with IL MAKIAGE's commitment to continue innovating and revolutionizing the beauty and wellness industries at-large. It also sets the stage for the company’s planned new brand launches within the beauty and wellness domains. The acquisition is the company’s second technology acquisition in the last 24 months.
Voyage81 is the first and only company in the world to develop patented software that brings hyperspectral imaging capabilities to smartphones. Voyage81’s software extracts over 30 channels of hyperspectral information from RGB images taken with existing smartphone cameras. In addition to its vision software, Voyage81 is currently developing a hardware-based solution, in tandem with some of the largest global smartphone manufacturers, that builds on the company’s hyperspectral software to significantly enhance photos taken in low-light conditions.
IL MAKIAGE CEO Oran Holtzman says, “For the past two years, we have been searching for computational imaging solutions that can work in beauty and wellness to further advance our existing AI capabilities. I have met dozens of computer vision startups but could not find a technology that can fit our industry and was strong enough to fulfill our goals. Bringing on Voyage81’s patented technology and exceptional team to our tech and data science departments is a huge win for our company's future, our users, and the industry at-large."
The implications of Voyage81's technology for the beauty and wellness industries are endless. Voyage81’s software is capable of mapping and analyzing skin and hair features, detecting facial blood flows, and creating melanin and hemoglobin maps from a simple smartphone camera photo. The technology, combined with IL MAKIAGE’s current AI algorithms, will leverage users' personal smartphone cameras to provide unparalleled online matching capabilities to users of IL MAKIAGE and its upcoming homegrown digital beauty and wellness brands.
Voyage81 was founded in 2019 by CEO Niv Price, former head of R&D at Unit 81, the most elite technological unit in the Israeli Defense Forces (the unit’s alumnus are known to have founded some of the most successful start-ups in Israel), Dr. Boaz Arad (CTO), a Ph.D. in Computer Vision and a key opinion leader in the hyperspectral space, Dr. Rafi Gidron, an accomplished and well-known Israeli hi-tech serial entrepreneur (including Chromatis Networks, sold to Lucent), and Omer Shwartz (Software Lead), a Ph.D. in Cyber Security.
Voyage81’s computer vision capabilities and team (half of whom hold PhDs) will be integrated within IL MAKIAGE's data science capabilities and its matching algorithms to serve the company's tens of millions of users and customers. Voyage81 founders, Niv Price, Dr. Arad and Omer Shwartz, will take leadership roles in IL MAKIAGE. Price will serve as CTO, Dr. Arad will serve as Chief Vision Officer, while Shwartz will serve as VP of Information Security. All three will also continue to lead Voyage81 as CEO, CTO and Software Lead.
“When we met Oran, we were focused on our own rapid growth trajectory with no plans at all to sell," notes Price, Voyage81 co-founder and CEO. "In fact, we just finished round A funding and were already working with the largest smartphone manufacturers in the world. But after meeting Oran and learning about the company’s long-term vision, we realized that under the IL MAKIAGE platform, Voyage81 technology will serve and benefit hundreds of millions of consumers, fulfilling our founding goal.”
"The technological advancements for IL MAKIAGE are immense," said Holtzman. "The software-only hyperspectral expansion, which requires only a traditional image from any smartphone camera, will be immediately integrated into the company's consumer experience. The addition of these vision capabilities provides another dimension of information which will allow us to rapidly expand our capabilities in existing and future domains with lower amount of data needed for our machine learning models."
Voyage81 co-founder and CTO, Dr. Arad said, “Combining Voyage81’s physics-based algorithms with IL MAKIAGE’s existing data science team and utilizing the company’s one billion+ data points and unprecedented daily incoming data flow, will further boost our AI vision capabilities. Thus, I strongly believe that together we can conquer the next frontier in the beauty and wellness industries – creating a technological advantage that will be next to impossible to match.”
Voyage81’s technology was developed based on the doctoral research of Dr. Arad who was examining by how much the estimation of hyperspectral information from RGB data would be inferior to professional hyperspectral camera results. When he saw that the results were almost comparable, he thought he had introduced some errors into the comparison process, but after deep investigation he realized he was on to an exciting discovery that has the potential to reverberate throughout the world.
About IL MAKIAGE
Launched in the US in 2018 by brother-sister duo entrepreneurs, IL MAKIAGE is a New York based, tech-driven prestige DTC beauty company. IL MAKIAGE is defining and building the future of beauty by using proprietary technology to connect people with superior, painstakingly tested, beauty products. Following the company’s major success as the fastest-growing online beauty brand in the US, IL MAKIAGE continues to shift millions of customers from offline to online and it recently expanded to the UK, Canada, Germany and Australia. IL MAKIAGE is backed by L Catterton, the leading consumer-focused private equity company in the world. For more information, visit www.ilmakiage.com.
About Voyage81
Founded in 2019, Voyage81 is a deep-tech AI-based computational imaging company that developed a patented software which recovers over 30 channels of hyperspectral information from any simple smartphone camera with no additional hardware, charting a path to revolutionize the beauty and wellness industries. Voyage81, led by alumni of the top elite Israeli intelligence units as well as computer vision PhDs, is also developing in partnership with some of the largest global smartphone manufacturers a hardware-based solution that builds on the company’s hyperspectral software to significantly enhance photos taken in low-light conditions. Voyage81 is backed by True Ventures, Next Gear Ventures, Maniv Mobility and iAngels. For more information, visit www.voyage81.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005438/en/
Contact information
For Media Inquiries:
Michael Braun
IL MAKIAGE
michaelb@ilmakiage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release
Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release
Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release
AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by
illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release
illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom